The global pharmaceutical industry, often called Big Pharma, sits at the crossroads of science, business, and public health. Its achievements have extended life expectancy, transformed deadly diseases into treatable conditions, and driven medical innovation on a global scale. Yet, behind these advances lies a deep ethical and economic challenge: the high cost of life-saving medicines. The question of who gets access to these treatments, and at what price, continues to spark debate in boardrooms, parliaments, and hospitals worldwide. Understanding how pharmaceutical companies set prices, how patent systems shape access, and how the balance between innovation and affordability affects law, business, and global health policy is central to understanding why Big Pharma is the way it is, and what its future can be.
How Pharmaceutical Companies Set Prices
Unlike most consumer goods, medicines are not priced based on production costs alone. Developing a new drug is an expensive and uncertain process. Pharmaceutical companies argue that high prices reflect not only manufacturing costs but also the billions spent on research and development, clinical trials, and regulatory approvals.
These, and other key factors influence how drug prices are set. First, the cost of research and development. Creating a successful drug can take over a decade and cost billions when failures are considered. Patent protection also plays a major role, as companies can set prices without competition and charge what the market can bear during the period of market exclusivity. The size of the target market also matters. Drugs for rare conditions, often called orphan drugs, may be priced extremely highly to recover costs from a small patient population. Finally, pricing depends on negotiation power. In countries with national health systems, governments negotiate directly with companies, while in others like the United States, prices are largely unregulated.
Critics argue that the link between price and research cost is often overstated. Controversies such as the EpiPen price increases in the United States have shown how market dominance can lead to inflated prices with little connection to innovation.
The Role of Patents in Access to Medicine
Patents are essential to the pharmaceutical business model, granting companies exclusive rights to manufacture and sell a drug for a period of roughly twenty years, allowing them to recover investment and earn profit. However, this protection also blocks generic competition, keeping prices high for long periods.
The international framework for patents is governed by the TRIPS Agreement under the World Trade Organisation. While this system aims to protect innovation, it has also been criticised for limiting access to affordable medicine in developing countries.
There are exceptions, such as compulsory licensing, which allows governments to authorise generic production without the patent holder’s consent during public health emergencies. This exemption has been used by countries like India and Brazil to supply cheaper HIV and AIDS drugs, but such actions often face political and trade pressure from wealthier nations and pharmaceutical lobbies.
Access to Medicine: Developed and Developing Countries
In developed countries, access to medicine is often supported by public healthcare or private insurance. While high prices still cause debate, most people eventually gain access through subsidies or negotiated rates.
The reality is often very different in developing countries. High drug prices can determine whether millions live or die. Without strong bargaining power or healthcare infrastructure, many countries pay more per dose relative to income levels.
A clear example is Sofosbuvir, a drug that cures Hepatitis C. When launched in the United States at eighty-four thousand dollars for a full course, it was unaffordable for most of the world. After global pressure, some countries were allowed to produce generic versions at less than one thousand dollars per treatment, but many middle-income nations were still left out.
The COVID-19 Effect: Spotlight on Pfizer and Moderna
These issues were magnified by the COVID-19 Pandemic. Pfizer and Moderna developed mRNA vaccines in record time; a remarkable scientific achievement that saved millions of lives. However, their pricing and patent strategies drew global criticism.
Wealthy countries secured priority access through advance purchase agreements, while many developing nations waited months or years for access to vaccines. Much of the underlying mRNA technology had been developed with public funding, yet private companies controlled its commercial use and limited knowledge sharing.
The COVAX initiative aimed to ensure fair global vaccine distribution but struggled due to supply hoarding and resistance to temporary patent waivers. The proposed TRIPS waiver for COVID-19 vaccines divided governments and companies, raising difficult questions about how far intellectual property protection should extend during global emergencies.
Commercial and Ethical Pressures
Pharmaceutical companies operate under competing pressures: shareholders expect profit and market growth, while the public expects fairness and accessibility. Without financial incentives, companies argue that innovation would slow down. However, there is also a clear moral duty to ensure access to essential medicines, particularly during health crises.
The balance between profit and public interest is not just about reputation. Ethical behaviour can affect regulation, trade negotiations, and even investment decisions. As environmental, social, and governance (ESG) standards grow in importance, the affordability of medicine has become a key issue for investors and policymakers.
Can Innovation and Affordability Coexist?
Finding a middle ground between innovation and access is possible, but it requires coordinated action across sectors:
Tiered pricing can allow companies to charge different prices across markets based on income levels, expanding access while maintaining profitability.
Public-private partnerships can reduce financial risk for companies and promote fairer distribution.
Open science and data sharing can accelerate research and reduce duplication.
Patent pooling, where companies voluntarily share patents, can enable generic production without undermining incentives for research.
These approaches depend on political will, regulatory reform, and public understanding of what fair pricing truly means.
Why This Matters for Law, Business, and Policy
The pharmaceutical sector influences far more than health outcomes. Its pricing and patent decisions shape global trade, affect national healthcare budgets, and influence diplomacy. Law firms working with pharmaceutical companies, governments, or NGOs must navigate complex intellectual property laws, ethical considerations, and regulatory frameworks.
For businesses, drug pricing affects investment decisions, supply chains, and market entry strategies. For policymakers, it challenges the balance between economic competitiveness and social responsibility. The pandemic made it clear that access to medicine is not only a public health issue but also a matter of economic security and global justice.
Sources
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820562
https://pubmed.ncbi.nlm.nih.gov/34368939/
https://www.brookings.edu/articles/five-things-to-understand-about-pharmaceutical-rd/
https://www.wired.com/story/drug-research-pricing/
https://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm
https://pubmed.ncbi.nlm.nih.gov/37646392/
https://www.cbo.gov/publication/57126
https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10374-y
“The WTO Waiver on COVID-19 Vaccine Patents | UCLA Law Review” — legal overview of the waiver proposal, its adoption in 2022 and remaining issues.
NEVER MISS A THING!
Subscribe and get freshly baked articles. Join the community!
Join the newsletter to receive the latest updates in your inbox.